Anticoagulation for Patients with CHA₂DS₂-VASc Score of 2

Risk Assessment and Recommendation

• The American College of Cardiology recommends the CHA₂DS₂-VASc score as the tool for assessing stroke risk in patients with atrial fibrillation, except those with moderate or severe mitral stenosis or mechanical heart valves 1, 2
• A CHA₂DS₂-VASc score of 2 corresponds to an adjusted stroke rate of approximately 2.2% per year without anticoagulation, according to the American College of Cardiology and European Heart Journal guidelines 3, 4
• The American College of Cardiology and European Heart Journal guidelines clearly recommend oral anticoagulation therapy for patients with a CHA₂DS₂-VASc score of 2 5, 6, 7
• The recommendation for oral anticoagulation applies regardless of whether the AF pattern is paroxysmal, persistent, or permanent, as stated by the American College of Cardiology 1

Anticoagulation Options

• The American College of Cardiology recommends Direct Oral Anticoagulants (DOACs) over warfarin in eligible patients with AF and CHA₂DS₂-VASc score of 2 1, 2
• Dabigatran is a recommended DOAC option for patients with AF and CHA₂DS₂-VASc score of 2, according to the European Heart Journal 7
• Edoxaban is another recommended DOAC option for patients with AF and CHA₂DS₂-VASc score of 2, as stated by the American College of Cardiology 8
• DOACs have been shown to be at least non-inferior and in some trials superior to warfarin for preventing stroke and systemic embolism with lower risks of serious bleeding, according to the American College of Cardiology 1

Alternative Option

• The American Heart Association recommends warfarin (target INR 2.0-3.0) as an alternative option if DOACs are contraindicated or not suitable for patients with AF and CHA₂DS₂-VASc score of 2 5, 3
• INR should be monitored at least weekly during initiation and monthly when stable for patients on warfarin, as recommended by the American College of Cardiology 1
• Warfarin may be considered for patients with severe renal impairment (CrCl <15 mL/min) or on hemodialysis, according to the American Heart Association 5

Special Considerations

• Renal function should be evaluated before initiating DOACs and reassessed at least annually, as recommended by the American Heart Association 5
• Bleeding risk should be assessed using the HAS-BLED score, but high bleeding risk alone should not exclude patients from anticoagulation, according to the European Heart Journal 6, 9
• The threshold for anticoagulation differs slightly between men and women, with a CHA₂DS₂-VASc score of ≥2 requiring anticoagulation for men and ≥3 for women, as stated by the American College of Cardiology 8, 10